OTC: NURPF - Neuren Pharmaceuticals Limited

Rentabilidade por seis meses: -21.88%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Neuren Pharmaceuticals Limited

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares.

mais detalhes
Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.neurenpharma.com
Цена ао 7.25
Alteração de preço por dia: 0% (7.25)
Alteração de preço por semana: -6.58% (7.7607)
Alteração de preço por mês: -13.28% (8.36)
Alteração de preço em 3 meses: -9.38% (8)
Mudança de preço em seis meses: -21.88% (9.28)
Mudança de preço por ano: -48.21% (14)
Mudança de preço em 3 anos: +137.35% (3.0545)
Mudança de preço em 5 anos: +279.58% (1.91)
Mudança de preço desde o início do ano: -11.8% (8.22)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 12.7 1
P/BV 14.35 1
P/E 18.75 7
EV/EBITDA 14.7 7
Total: 5.63

Eficiência

Nome Significado Nota
ROA, % 63.35 10
ROE, % 76.55 10
Total: 8.33

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA 0 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 46756.97 10
Rentabilidade Ebitda, % -1821.79 0
Rentabilidade EPS, % -2025.02 0
Total: 2
Mais detalhes

Instituições Volume Compartilhar, %
Vanguard International Stock Index-Total Intl Stock Indx 1480133 1.16
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 877162 0.69
iShares Core MSCI EAFE ETF 652944 0.51
iShares MSCI EAFE Small Cap ETF 436465 0.34
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 403572 0.32
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 215442 0.17
iShares Core MSCI Total International Stock ETF 140892 0.11
Vanguard International Stock Index-Pacific Stock Index 128668 0.1
College Retirement Equities Fund-Stock Account 85378 0.07
SEI Institutional International Tr-International Equity 71485 0.06



Supervisor Cargo Pagamento Ano de nascimento
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director 714.28k
Ms. Lauren Frazer C.A. CFO & Company Secretary N/A
Mr. Lawrence Glass BA (Biology) Chief Science Officer N/A
Mr. Gerry Zhao Vice President of Corporate Development N/A
Dr. Liza A. Squires M.D. Chief Medical Officer N/A

Endereço: Australia, Camberwell, 697 Burke Road - abrir no Google Maps, abrir mapas Yandex
Site: https://www.neurenpharma.com